NCT01263951View on ClinicalTrials.gov

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

PHASE2UnknownINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

February 1, 2021

Study Completion Date

May 31, 2022

Conditions
Differentiated Thyroid Cancer
Interventions
DRUG

Everolimus

One 5 mg. tablet daily.

DRUG

Sorafenib

200 mg. twice daily.

Trial Locations (1)

19104

Hospital of the University of Pennsylvania, Philadelphia

Sponsors
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Thomas Jefferson University

OTHER